BioCentury | Jan 11, 2013
Financial News

Esanex raises $500,000 from BioCrossroads

...SVP of R&D of Serenex Inc. , which Pfizer Inc. (NYSE:PFE) acquired in 2008. Pfizer gained Serenex's...
BioCentury | Mar 21, 2011
Product Development

Safe to move forward vs. Hsp90

...the compound caused "reversible visual disturbances." The pharma obtained PF-04929113 through its 2008 acquisition of Serenex Inc....
BioCentury | Dec 15, 2008
Finance

Ebb & Flow

...Richard Kent joined Intersouth Partners as a venture partner. He was President and CEO of Serenex...
BioCentury | Mar 10, 2008
Company News

Serenex, Pfizer deal

...Pfizer will acquire Serenex for an undisclosed sum. The acquisition gives Pfizer SNX-5422 , an oral...
...advised Serenex on the deal, which is expected to close next quarter. The deal excludes Serenex's...
...entity held by Serenex shareholders. Pfizer said the therapy was outside its area of interest. Serenex Inc....
BioCentury | Mar 10, 2008
Strategy

Hsp90 pipline

...Ph II (HRPC), non-small cell lung cancer (NSCLC), Ph I/II (NSCLC), GIST Ph I (GIST) Serenex...
BioCentury | Mar 10, 2008
Finance

Ebb & Flow

...heat shock protein 90 inhibitors fell last week after Pfizer's acquisition of oral Hsp90 company Serenex...
...purine-binding proteins (see "Focus Pays Off," A9). The pharma will spin back one program to Serenex...
BioCentury | Mar 10, 2008
Strategy

Focus pays off for Serenex

...By acquiring Serenex Inc. for an undisclosed sum, Pfizer Inc. gets one of only two oral heat...
...90 inhibitors in the clinic for cancer. As a bonus, the pharma company also gets Serenex's...
..."Our singular focus on Hsp90 was a practical one," Steven Hall, SVP of R&D at Serenex...
BioCentury | Mar 4, 2008
Company News

Pfizer acquiring Serenex

...Pfizer (NYSE:PFE) will acquire Serenex (Durham, N.C.) for an undisclosed amount. The acquisition gives Pfizer SNX-5422...
...advised Serenex on the deal, which is expected to close next quarter. The deal excludes Serenex's...
...are expected in June. Serenex said SNX-1012 will be transferred to an entity held by Serenex...
BioCentury | Mar 3, 2008
Clinical News

SNX-5422: Phase I start

...Serenex will begin an open-label, U.S. Phase I trial of oral SNX-5422 in 30-50 patients. Serenex Inc....
BioCentury | Jan 21, 2008
Company News

Serenex, CHDI Inc. deal

...CHDI will assess Serenex's small molecule Hsp90 inhibitors as potential therapeutics for Huntington's disease (HD). Serenex...
...will retain all rights to develop and commercialize the molecules. Further terms were not disclosed. Serenex Inc....
Items per page:
1 - 10 of 40
BioCentury | Jan 11, 2013
Financial News

Esanex raises $500,000 from BioCrossroads

...SVP of R&D of Serenex Inc. , which Pfizer Inc. (NYSE:PFE) acquired in 2008. Pfizer gained Serenex's...
BioCentury | Mar 21, 2011
Product Development

Safe to move forward vs. Hsp90

...the compound caused "reversible visual disturbances." The pharma obtained PF-04929113 through its 2008 acquisition of Serenex Inc....
BioCentury | Dec 15, 2008
Finance

Ebb & Flow

...Richard Kent joined Intersouth Partners as a venture partner. He was President and CEO of Serenex...
BioCentury | Mar 10, 2008
Company News

Serenex, Pfizer deal

...Pfizer will acquire Serenex for an undisclosed sum. The acquisition gives Pfizer SNX-5422 , an oral...
...advised Serenex on the deal, which is expected to close next quarter. The deal excludes Serenex's...
...entity held by Serenex shareholders. Pfizer said the therapy was outside its area of interest. Serenex Inc....
BioCentury | Mar 10, 2008
Strategy

Hsp90 pipline

...Ph II (HRPC), non-small cell lung cancer (NSCLC), Ph I/II (NSCLC), GIST Ph I (GIST) Serenex...
BioCentury | Mar 10, 2008
Finance

Ebb & Flow

...heat shock protein 90 inhibitors fell last week after Pfizer's acquisition of oral Hsp90 company Serenex...
...purine-binding proteins (see "Focus Pays Off," A9). The pharma will spin back one program to Serenex...
BioCentury | Mar 10, 2008
Strategy

Focus pays off for Serenex

...By acquiring Serenex Inc. for an undisclosed sum, Pfizer Inc. gets one of only two oral heat...
...90 inhibitors in the clinic for cancer. As a bonus, the pharma company also gets Serenex's...
..."Our singular focus on Hsp90 was a practical one," Steven Hall, SVP of R&D at Serenex...
BioCentury | Mar 4, 2008
Company News

Pfizer acquiring Serenex

...Pfizer (NYSE:PFE) will acquire Serenex (Durham, N.C.) for an undisclosed amount. The acquisition gives Pfizer SNX-5422...
...advised Serenex on the deal, which is expected to close next quarter. The deal excludes Serenex's...
...are expected in June. Serenex said SNX-1012 will be transferred to an entity held by Serenex...
BioCentury | Mar 3, 2008
Clinical News

SNX-5422: Phase I start

...Serenex will begin an open-label, U.S. Phase I trial of oral SNX-5422 in 30-50 patients. Serenex Inc....
BioCentury | Jan 21, 2008
Company News

Serenex, CHDI Inc. deal

...CHDI will assess Serenex's small molecule Hsp90 inhibitors as potential therapeutics for Huntington's disease (HD). Serenex...
...will retain all rights to develop and commercialize the molecules. Further terms were not disclosed. Serenex Inc....
Items per page:
1 - 10 of 40